← Back to Events
Tier 1 Global Networking: High GENERAL CONCLUDED
2026 U.S.-Japan Healthcare — Not specified, USA, United States
<p>*In-person program Come hear pitches from leading Japanese strategic investors and pharmaceutical companies including AN Ventures, Astellas, Chugai Pharmaceuticals, Daiichi Sankyo, Nippon Life, and Ono Pharmaceuticals. Our presenters will share…</p>\n
75+ Attendees
9 Presentations
3 Companies
2 Drugs
Presentation data updated Jun 15, 2026, 9:35 PM UTC
Nova Event Impact Score
62 /100
- Media coverage 20/20
- Speaker quality 14/20
- Pipeline relevance 2/20
- Historical influence 20/20
- Company participation 6/20
Key Takeaways
Key Themes
generalUSA-Japan Society, Biocom, JETROPipeline announcementsPartnership deals
Key Companies
AstraZenecaXenon PharmaceuticalsInsmed
Key Drugs
trastuzumab deruxtecanazetukalner
Key Markets
US Americas
Key Opportunities
Partnership dealsLicensing discussionsVendor selection
Investors & analysts
Key Data to Watch
ORAL
Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS) final data readout
ORAL
Phase 3 ENCORE trial topline readout in patients with newly diagnosed or recurrent disease